• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肺腺癌中切割与聚腺苷酸化特异性因子4的上调及其对癌细胞存活和增殖的关键作用。

Upregulation of cleavage and polyadenylation specific factor 4 in lung adenocarcinoma and its critical role for cancer cell survival and proliferation.

作者信息

Chen Wangbing, Guo Wei, Li Mei, Shi Dingbo, Tian Yun, Li Zhenlin, Wang Jingshu, Fu Lingyi, Xiao Xiangsheng, Liu Quentin Qiang, Wang Shusen, Huang Wenlin, Deng Wuguo

机构信息

State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.

Institute of Cancer Stem Cell, Dalian Medical University Cancer Center, Dalian, China.

出版信息

PLoS One. 2013 Dec 16;8(12):e82728. doi: 10.1371/journal.pone.0082728. eCollection 2013.

DOI:10.1371/journal.pone.0082728
PMID:24358221
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3865097/
Abstract

Cleavage and polyadenylation specific factor 4 (CPSF4), a member of CPSF complex, plays a key role in mRNA polyadenylation and mRNA 3' ends maturation. However, its possible role in lung cancer pathogenesis is unknown. In this study, we investigated the biological role and clinical significance of CPSF4 in lung cancer growth and survival and elucidated its underlying molecular mechanisms. We found that CPSF4 was highly expressed in lung adenocarcinoma cell lines and tumor tissue but was undetectable in 8 normal human tissues. We also found that CPSF4 overexpression was correlated with poor overall survival in patients with lung adenocarcinomas (P<0.001). Multivariate survival analyses revealed that higher CPSF4 expression was an independent prognostic factor for overall survival of the patients with lung adenocarcinomas. Suppression of CPSF4 by siRNA inhibited lung cancer cells proliferation, colony formation, and induced apoptosis. Mechanism studies revealed that these effects were achieved through simultaneous modulation of multiple signaling pathways. Knockdown of CPSF4 expression by siRNA markedly inhibited the phosphorylation of PI3K, AKT and ERK1/2 and JNK proteins. In contrast, the ectopic expression of CPSF4 had the opposite effects. Moreover, CPSF4 knockdown also induced the cleavage of caspase-3 and caspse-9 proteins. Collectively, these results demonstrate that CPSF4 plays a critical role in regulating lung cancer cell proliferation and survival and may be a potential prognostic biomarker and therapeutic target for lung adenocarcinoma.

摘要

切割与聚腺苷酸化特异性因子4(CPSF4)是CPSF复合物的成员之一,在mRNA聚腺苷酸化和mRNA 3'末端成熟过程中发挥关键作用。然而,其在肺癌发病机制中的潜在作用尚不清楚。在本研究中,我们调查了CPSF4在肺癌生长和存活中的生物学作用及临床意义,并阐明了其潜在的分子机制。我们发现CPSF4在肺腺癌细胞系和肿瘤组织中高表达,但在8种正常人体组织中未检测到。我们还发现CPSF4过表达与肺腺癌患者的总生存期较差相关(P<0.001)。多因素生存分析显示,较高的CPSF4表达是肺腺癌患者总生存期的独立预后因素。通过小干扰RNA(siRNA)抑制CPSF4可抑制肺癌细胞增殖、集落形成并诱导凋亡。机制研究表明,这些作用是通过同时调节多个信号通路实现的。用siRNA敲低CPSF4表达可显著抑制PI3K、AKT以及ERK1/2和JNK蛋白的磷酸化。相反,CPSF4的异位表达则产生相反的效果。此外,敲低CPSF4还可诱导caspase-3和caspase-9蛋白的切割。总体而言,这些结果表明CPSF4在调节肺癌细胞增殖和存活中起关键作用,可能是肺腺癌潜在的预后生物标志物和治疗靶点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8258/3865097/a852e06db991/pone.0082728.g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8258/3865097/62dfd316579a/pone.0082728.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8258/3865097/a163df305d67/pone.0082728.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8258/3865097/02034a56e7e0/pone.0082728.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8258/3865097/8a2d8054e6b5/pone.0082728.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8258/3865097/a852e06db991/pone.0082728.g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8258/3865097/62dfd316579a/pone.0082728.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8258/3865097/a163df305d67/pone.0082728.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8258/3865097/02034a56e7e0/pone.0082728.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8258/3865097/8a2d8054e6b5/pone.0082728.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8258/3865097/a852e06db991/pone.0082728.g005.jpg

相似文献

1
Upregulation of cleavage and polyadenylation specific factor 4 in lung adenocarcinoma and its critical role for cancer cell survival and proliferation.肺腺癌中切割与聚腺苷酸化特异性因子4的上调及其对癌细胞存活和增殖的关键作用。
PLoS One. 2013 Dec 16;8(12):e82728. doi: 10.1371/journal.pone.0082728. eCollection 2013.
2
CPSF4 activates telomerase reverse transcriptase and predicts poor prognosis in human lung adenocarcinomas.CPSF4激活端粒酶逆转录酶并预示人类肺腺癌预后不良。
Mol Oncol. 2014 May;8(3):704-16. doi: 10.1016/j.molonc.2014.02.001. Epub 2014 Feb 14.
3
CREB-binding protein regulates lung cancer growth by targeting MAPK and CPSF4 signaling pathway.CREB结合蛋白通过靶向丝裂原活化蛋白激酶(MAPK)和切割及聚腺苷酸化特异性因子4(CPSF4)信号通路来调节肺癌生长。
Mol Oncol. 2016 Feb;10(2):317-29. doi: 10.1016/j.molonc.2015.10.015. Epub 2015 Nov 5.
4
Cleavage and polyadenylation specific factor 4 targets NF-κB/cyclooxygenase-2 signaling to promote lung cancer growth and progression.剪接因子 4 靶向 NF-κB/环氧化酶-2 信号通路促进肺癌生长和进展。
Cancer Lett. 2016 Oct 10;381(1):1-13. doi: 10.1016/j.canlet.2016.07.016. Epub 2016 Jul 20.
5
Cleavage and polyadenylation specific factor 4 promotes colon cancer progression by transcriptionally activating hTERT.剪接因子 4 通过转录激活端粒酶逆转录酶促进结肠癌的进展。
Biochim Biophys Acta Mol Cell Res. 2019 Oct;1866(10):1533-1543. doi: 10.1016/j.bbamcr.2019.07.001. Epub 2019 Jul 10.
6
Suppression of cleavage factor Im 25 promotes the proliferation of lung cancer cells through alternative polyadenylation.抑制剪接因子 Im 25 通过可变多聚腺苷酸化促进肺癌细胞的增殖。
Biochem Biophys Res Commun. 2018 Sep 5;503(2):856-862. doi: 10.1016/j.bbrc.2018.06.087. Epub 2018 Jun 23.
7
Overproduced CPSF4 Promotes Cell Proliferation and Invasion via PI3K-AKT Signaling Pathway in Oral Squamous Cell Carcinoma.过量产生的CPSF4通过PI3K-AKT信号通路促进口腔鳞状细胞癌的细胞增殖和侵袭。
J Oral Maxillofac Surg. 2021 May;79(5):1177.e1-1177.e14. doi: 10.1016/j.joms.2020.12.047. Epub 2021 Jan 5.
8
Downregulation of NMI promotes tumor growth and predicts poor prognosis in human lung adenocarcinomas.NMI 的下调促进了人类肺腺癌的肿瘤生长,并预示着不良的预后。
Mol Cancer. 2017 Oct 12;16(1):158. doi: 10.1186/s12943-017-0705-9.
9
MiR-4458 inhibits breast cancer cell growth, migration, and invasiveness by targeting CPSF4.miR-4458 通过靶向 CPSF4 抑制乳腺癌细胞的生长、迁移和侵袭。
Biochem Cell Biol. 2019 Dec;97(6):722-730. doi: 10.1139/bcb-2019-0008. Epub 2019 Apr 10.
10
CPSF4 promotes tumor-initiating phenotype by enhancing VEGF/NRP2/TAZ signaling in lung cancer.CPSF4通过增强肺癌中的VEGF/NRP2/TAZ信号传导来促进肿瘤起始表型。
Med Oncol. 2022 Dec 26;40(1):62. doi: 10.1007/s12032-022-01919-1.

引用本文的文献

1
Knockdown of STK39 inhibits lung cancer brain metastasis by suppressing the CPSF4/NFκB/COX2 pathway.敲低STK39通过抑制CPSF4/NFκB/COX2信号通路抑制肺癌脑转移。
J Neurooncol. 2025 May 21. doi: 10.1007/s11060-025-05072-3.
2
Fateful Decisions of Where to Cut the Line: Pathology Associated with Aberrant 3' End Processing and Transcription Termination.决定切割位置的关键抉择:与异常3'端加工及转录终止相关的病理学
J Mol Biol. 2025 Jan 1;437(1):168802. doi: 10.1016/j.jmb.2024.168802. Epub 2024 Sep 24.
3
Modulation of diverse biological processes by CPSF, the master regulator of mRNA 3' ends.

本文引用的文献

1
Development of PI3K/AKT/mTOR pathway inhibitors and their application in personalized therapy for non-small-cell lung cancer.PI3K/AKT/mTOR 通路抑制剂的研发及其在非小细胞肺癌个体化治疗中的应用。
J Thorac Oncol. 2012 Aug;7(8):1315-26. doi: 10.1097/JTO.0b013e31825493eb.
2
Insulin-like growth factor-1 receptor (IGF-1R) kinase inhibitors in cancer therapy: advances and perspectives.胰岛素样生长因子-1 受体 (IGF-1R) 激酶抑制剂在癌症治疗中的应用:进展与展望。
Curr Pharm Des. 2012;18(20):2901-13. doi: 10.2174/138161212800672723.
3
The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches.
CPSF 对多种生物过程的调节作用,CPSF 是 mRNA 3' 端的主要调节因子。
RNA. 2024 Aug 16;30(9):1122-1140. doi: 10.1261/rna.080108.124.
4
Cleavage and polyadenylation machinery as a novel targetable vulnerability for human cancer.切割与聚腺苷酸化机制作为人类癌症一种新的可靶向性弱点。
Cancer Gene Ther. 2024 Jul;31(7):957-960. doi: 10.1038/s41417-024-00770-y. Epub 2024 Apr 17.
5
HNRNPK/CLCN3 axis facilitates the progression of LUAD through CAF-tumor interaction.HNRNPK/CLCN3 轴通过 CAF-肿瘤相互作用促进 LUAD 的进展。
Int J Biol Sci. 2022 Oct 17;18(16):6084-6101. doi: 10.7150/ijbs.76083. eCollection 2022.
6
Silencing of inhibits the proliferation, migration, and invasion of lung adenocarcinoma cells by blocking the AKT/mTOR signaling pathway.[基因名称]的沉默通过阻断AKT/mTOR信号通路抑制肺腺癌细胞的增殖、迁移和侵袭。
Open Med (Wars). 2022 Oct 21;17(1):1655-1663. doi: 10.1515/med-2022-0570. eCollection 2022.
7
Hemocyte Clusters Defined by scRNA-Seq in : Analysis of Predicted Marker Genes and Implications for Potential Functional Roles.scRNA-Seq 定义的血淋巴细胞簇:预测标记基因分析及潜在功能作用的启示。
Front Immunol. 2022 Feb 25;13:852702. doi: 10.3389/fimmu.2022.852702. eCollection 2022.
8
Emerging Roles of RNA 3'-end Cleavage and Polyadenylation in Pathogenesis, Diagnosis and Therapy of Human Disorders.RNA 3'-端切割和多聚腺苷酸化在人类疾病发病机制、诊断和治疗中的新兴作用。
Biomolecules. 2020 Jun 17;10(6):915. doi: 10.3390/biom10060915.
9
CPSF3 is a promising prognostic biomarker and predicts recurrence of non-small cell lung cancer.CPSF3是一种很有前景的预后生物标志物,可预测非小细胞肺癌的复发。
Oncol Lett. 2019 Sep;18(3):2835-2844. doi: 10.3892/ol.2019.10659. Epub 2019 Jul 24.
10
Temporal Proteomic Analysis of Pancreatic β-Cells in Response to Lipotoxicity and Glucolipotoxicity.脂毒性和糖脂毒性作用下胰岛β细胞的时间蛋白质组学分析。
Mol Cell Proteomics. 2018 Nov;17(11):2119-2131. doi: 10.1074/mcp.RA118.000698. Epub 2018 Aug 6.
RAS/RAF/MEK/ERK 和 PI3K/AKT 信号通路:在癌症发病机制中的作用及其对治疗方法的影响。
Expert Opin Ther Targets. 2012 Apr;16 Suppl 2:S17-27. doi: 10.1517/14728222.2011.639361. Epub 2012 Mar 23.
4
Cancer statistics, 2012.癌症统计数据,2012 年。
CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29. doi: 10.3322/caac.20138. Epub 2012 Jan 4.
5
Oncogenic pathways, molecularly targeted therapies, and highlighted clinical trials in non-small-cell lung cancer (NSCLC).致癌途径、分子靶向治疗以及非小细胞肺癌(NSCLC)中的重点临床试验。
Clin Lung Cancer. 2012 Jul;13(4):252-66. doi: 10.1016/j.cllc.2011.09.004. Epub 2011 Dec 8.
6
Characterization of a cleavage stimulation factor, 3' pre-RNA, subunit 2, 64 kDa (CSTF2) as a therapeutic target for lung cancer.鉴定一种剪接刺激因子,3' 前 RNA,亚基 2,64kDa(CSTF2)作为肺癌的治疗靶点。
Clin Cancer Res. 2011 Sep 15;17(18):5889-900. doi: 10.1158/1078-0432.CCR-11-0240. Epub 2011 Aug 3.
7
Functional analysis of HOXD9 in human gliomas and glioma cancer stem cells.HOXD9 在人类脑胶质瘤和脑胶质瘤肿瘤干细胞中的功能分析。
Mol Cancer. 2011 May 22;10:60. doi: 10.1186/1476-4598-10-60.
8
Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.吉非替尼或化疗用于治疗具有突变型 EGFR 的非小细胞肺癌。
N Engl J Med. 2010 Jun 24;362(25):2380-8. doi: 10.1056/NEJMoa0909530.
9
Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.携带EML4-ALK的非小细胞肺癌患者的临床特征及预后
J Clin Oncol. 2009 Sep 10;27(26):4247-53. doi: 10.1200/JCO.2009.22.6993. Epub 2009 Aug 10.
10
Inositol 1,4,5-triphosphate receptor-binding protein released with inositol 1,4,5-triphosphate (IRBIT) associates with components of the mRNA 3' processing machinery in a phosphorylation-dependent manner and inhibits polyadenylation.与肌醇1,4,5-三磷酸(IP3)一同释放的肌醇1,4,5-三磷酸受体结合蛋白(IRBIT)以磷酸化依赖的方式与mRNA 3'加工机制的组分结合,并抑制多聚腺苷酸化。
J Biol Chem. 2009 Apr 17;284(16):10694-705. doi: 10.1074/jbc.M807136200. Epub 2009 Feb 18.